StreetAlpha.app
Home › Stocks › LBRX

LB Pharmaceuticals Inc (LBRX)

$38.85
▼ −2.97%
LAST CLOSE · NOV 20

LB Pharmaceuticals is a New York drug developer focused on LB-102, a candidate for schizophrenia and mood disorders. It last closed at $38.85 on Nov 20, down 2.97% on the day. The next earnings report for LBRX is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, LBRX reported EPS of -$1.79. Over its last 5 reports the stock moved an average of 4.5% the session after earnings.

AI Auto Pilots
Is LBRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LBRX.

Key Stats

Last 12 months
Results
Net income
−$141.2M
EPS (diluted)
−$1.12
Free cash flow
−$143.8M
Valuation
Market cap
$1.3B
32.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$215.1M
At Sep 30
Shareholder equity
$417.6M
Shares outstanding
32.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$63.1M−$63.1MFY2024FY2025: −$25.2M−$25.2MFY2025

From LBRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$1.79
Quarter ended Sep 2026
Year ago EPS
-$0.61
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$14.00Dec '24Mar 2025: -$14.79Mar '25Jun 2025: -$13.58Jun '25Sep 2025: -$0.61Sep '25Dec 2025: $3.13Dec '25Mar 2026: -$0.67Mar '26Jun 2026: -$1.71Jun '26Sep 2026: -$1.79Sep '26Latest -$1.79
Revenue by quarter
Not enough quarters on file yet.
How LBRX moved after its last 5 reports
Average move the session after a report ±4.5%
Nov 5, 2026After the close+10.3%
Aug 11, 2026Time not announced−1.1%
May 12, 2026After the close+3.8%
Mar 26, 2026After the close−2.8%
Nov 6, 2025Time not announced−4.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LBRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LBRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LBRX

Technical Analysis

LBRX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 6% below its 20 day and 2% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the Pivot S1 at $38.06, and the nearest resistance the swing high (Sep 30) at $39.23.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.8%/day
Key levels
$50.1652 week high+29.1%
$41.0720 day average+5.7%
$40.59100 day average+4.5%
$40.16Pivot R1+3.4%
$39.4950 day average+1.6%
$39.36Pivot+1.3%
$39.23Swing high (Sep 30)+1.0%
$38.85Last close
$38.06Pivot S1−2.0%
$37.98Swing low (Nov 5)−2.2%
$34.04200 day average−12.4%
$15.1952 week low−60.9%
Indicators
RSI (14)43.78Middle of its rangeNeutral
MACD0.32Below its signal lineBearish
Stochastic21.4Middle of its rangeNeutral
ADX (14)22.5Weak trend
Williams %R-88.9Oversold below −80, overbought above −20Oversold
CCI (20)-73.9Oversold below −100, overbought above 100Neutral
Rate of change−7.5%Change over 10 sessionsBearish
ATR (14)$2.66Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for LBRX

What happened before

See how LBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for LBRXHow many large options trades hit LBRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LBRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲100 buying vs 39 selling
  • ▲Held by funds +10.3 pts
  • ▲Funds holding +32
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding147115+27.8%
In funds' top 1075+40.0%
Held by funds105.5%95.2%+10.3 pts
New / increased42 / 5841 / 42+20.5%
Reduced / sold out28 / 1113 / 3+143.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LBRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LBRX Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 12, 2025Vida Ventures GP III, L.L.C.10% ownerBuy333,333$15.00$5.0M
Sep 12, 2025Ran NussbaumDirectorBuy1,000,000$15.00$15.0M
Sep 12, 2025Pontifax Management 4 G.P. (2015) Ltd.10% ownerBuy1,000,000$15.00$15.0M
Sep 12, 2025Deep Track Capital, LP10% ownerBuy2,666,666$15.00$40.0M
Every insider buy and sale for LBRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LBRX insider trades →

From SEC Form 4 filings by LBRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LBRX is in one of them and how their past LBRX trades turned out.

LBRX in the AI portfolios
Loading…

LBRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LBRX in an article yet. Here's the latest on the wider market.

LBRX in the news

About LB Pharmaceuticals

LB Pharmaceuticals is a biopharmaceutical company based in New York that develops treatments for neuropsychiatric disorders. Its main product candidate, LB-102, is in late-stage testing for schizophrenia and bipolar depression, with a planned study in major depressive disorder as a supplemental treatment. LB-102 is a chemical relative of amisulpride, an antipsychotic already used in many countries outside the United States. The company aims to offer its treatments to patients and to the psychiatrists who prescribe for them.

Headquarters
New York, NY